RNA

RNA is trading as a high-conviction 'Special Situation' arbitrage play, anchored by its pending $12B acquisition by Novartis ($72/share cash) and the associated spin-off of Atrium Therapeutics. The 'ALPHA_MALE' and 'STEADY_CLIMB' signals are not speculative momentum, but rather the precise tightening of the merger arbitrage spread as the deal progresses. While the broader market suffers a 'Tech Wreck' under the CAUTION regime, RNA's relative strength (+1.9% vs SPY) confirms its decoupling from macro beta due to the definitive deal terms.